valproic acid has been researched along with Nasopharyngeal Carcinoma in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Nasopharyngeal Carcinoma: A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the incidence of distant metastasis remains 25-34 %." | 2.80 | Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. ( de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalić, Z; Stoker, SD; Tan, IB; Verkuijlen, SA; Wildeman, MA, 2015) |
| "Valproic acid (VPA) was combined with gemcitabine (GCb) to stimulate EBV reactivation, followed by antiviral treatment with ganciclovir (GCV)." | 1.46 | Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model. ( de Greeuw, I; Eersels, JLH; Greijer, AE; Middeldorp, JM; Molthoff, CFM; Novalić, Z; Verkuijlen, SAWM; Verlaan, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Novalić, Z | 3 |
| Verkuijlen, SAWM | 1 |
| Verlaan, M | 1 |
| Eersels, JLH | 1 |
| de Greeuw, I | 1 |
| Molthoff, CFM | 1 |
| Middeldorp, JM | 3 |
| Greijer, AE | 3 |
| Stoker, SD | 1 |
| Wildeman, MA | 2 |
| Huitema, AD | 2 |
| Verkuijlen, SA | 2 |
| Juwana, H | 2 |
| Tan, IB | 2 |
| de Boer, JP | 2 |
| Strazzulla, A | 1 |
| Barreca, GS | 1 |
| Giancotti, A | 1 |
| Pisani, V | 1 |
| Costa, C | 1 |
| Zicca, E | 1 |
| La Boria, A | 1 |
| Roveda, L | 1 |
| Liberto, MC | 1 |
| Tucci, L | 1 |
| Donato, G | 1 |
| Focà, A | 1 |
| Torti, C | 1 |
| Hsu, CL | 1 |
| Kuo, YC | 1 |
| Huang, Y | 1 |
| Huang, YC | 1 |
| Lui, KW | 1 |
| Chang, KP | 1 |
| Lin, TL | 1 |
| Fan, HC | 1 |
| Lin, AC | 1 |
| Hsieh, CH | 1 |
| Lee, LY | 1 |
| Wang, HM | 1 |
| Li, HP | 1 |
| Chang, YS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for valproic acid and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, | 2015 |
1 trial available for valproic acid and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; | 2015 |
3 other studies available for valproic acid and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Topics: Animals; Antiviral Agents; Carcinoma; Deoxycytidine; Disease Models, Animal; DNA, Viral; Epstein-Bar | 2017 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; C | 2015 |
Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Topics: Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Deox | 2012 |